Iovance Biotherapeutics (IOVA) FCF Margin (2023 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly FCF Margin of 110.19% for Q1 2026, up 11263.0% year-over-year from N/an in Q1 2025, and down 54.52% quarter-over-quarter from 71.31% in Q4 2025.
Powered by 
Analysis
Iovance Biotherapeutics (IOVA) FCF Margin (2023 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported FCF Margin for 4 consecutive years, with 110.19% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin rose 11263.0% year-over-year to 110.19%; the TTM figure through Mar 2026 stood at 106.8% (up 5659.0% YoY), while the FY2025 annual figure was 127.6%, up 9428.0% from the prior year.
- FCF Margin fell to 110.19% in Q1 2026 per IOVA's latest filing, from 71.31% in the prior quarter.
- Across five years, FCF Margin topped out at 71.31% in Q4 2025 and bottomed at 43475.63% in Q2 2023.
- Historically, FCF Margin has averaged 8266.22% across 4 years, with a median of 177.82% in 2025.
- Annual changes were most pronounced in 2024 — FCF Margin surged 4315778 bps — and 2025, when it sank 2819 bps.
- Iovance Biotherapeutics' FCF Margin stood at 18153.32% in 2023, then surged by 99 bps to 105.12% in 2024, then surged by 32 bps to 71.31% in 2025, then sank by 55 bps to 110.19% in 2026.
- Business Quant data shows IOVA's FCF Margin at 110.19% in Q1 2026, 71.31% in Q4 2025, and 132.81% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Iovance Biotherapeutics | 3.95 Bn | 3.66 Bn | 55.72 Mn | -66.71% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -66.71% |
| Mar 31, 2026 | -110.19% |
| Dec 31, 2025 | -71.32% |
| Sep 30, 2025 | -132.75% |
| Jun 30, 2025 | -124.95% |
| Mar 31, 2025 | -222.82% |
| Dec 31, 2024 | -105.12% |
| Sep 30, 2024 | -104.62% |
| Jun 30, 2024 | -317.85% |
| Mar 31, 2024 | -17,685.31% |
| Dec 31, 2023 | -18,153.32% |
| Sep 30, 2023 | -18,690.83% |
| Jun 30, 2023 | -42,587.82% |